Achieve Life Sciences is no longer publicly traded under ACHV. The ticker stopped returning market quotes on Nov 22, 2026, which usually means the company was delisted, acquired or taken private.
Achieve Life Sciences (ACHV) is a Health Care company in the Russell 2000.
Current price targets from 4 firms average $14.5, median $13, ranging from $12 to $20. Each is tracked to its date and scored the same way a member's call is.
4 targets, newest first. Open a row for its source and scoring.
Entry price $7.25, the close nearest Aug 13, 2026, when the target was reported; the target is +176% from it.
Horizon No horizon stated, so it is tracked over the 12-month default, to Aug 2027.
Scoring Open: judged on the close on Aug 13, 2027.
Raymond James resumed coverage with a Strong Buy rating and set a $20.00 price target
Entry price $7.25, the close nearest Aug 13, 2026, when the target was reported; the target is +79% from it.
Horizon No horizon stated, so it is tracked over the 12-month default, to Aug 2027.
Scoring Open: judged on the close on Aug 13, 2027.
Canaccord Genuity also reiterated a Buy rating with a $13.00 price target
Entry price $7.25, the close nearest Aug 13, 2026, when the target was reported; the target is +66% from it.
Horizon No horizon stated, so it is tracked over the 12-month default, to Aug 2027.
Scoring Open: judged on the close on Aug 13, 2027.
H.C. Wainwright reiterated its Buy rating on the company, maintaining a $12.00 price target
Entry price $7.25, the close nearest Aug 13, 2026, when the target was reported; the target is +79% from it.
Horizon No horizon stated, so it is tracked over the 12-month default, to Aug 2027.
Scoring Open: judged on the close on Aug 13, 2027.
Morgan Stanley initiated coverage on Achieve Life Sciences with an overweight rating and a price target of $13.00.
Targets published by research firms, extracted from the news, checked against independent reporting, and linked to their source. Where a firm did not state a horizon the target is tracked as 12 months, the industry convention; the rows where the firm set its own horizon are marked. “At” is the closing price nearest the day the target was reported, the price we score it from; it is not an earlier target. Reported here as facts about what was published — not recommendations from Dalsna Finance, and no firm listed is affiliated with this site.
| FY2016Dec 2016 | FY2017Dec 2017 | FY2018Dec 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | — | — | $0 | $0 | — | — | — | — | — | — |
| Net income | −$1.23M | −$10.6M | −$12.7M | −$16.4M | −$14.7M | −$33.2M | −$42.4M | −$29.8M | −$39.8M | −$54.6M |
| EPS (diluted) | −$232500.00 | −$8828.00 | −$72.29 | −$39.76 | −$5.42 | −$4.08 | −$4.00 | −$1.50 | −$1.24 | −$1.25 |
| Balance sheet | ||||||||||
| Cash and equivalents | $15.0K | $5.28M | $9.52M | $16.7M | $35.9M | $43.0M | $24.8M | $15.5M | $12.8M | $20.9M |
| Total assets | $3.81M | $9.89M | $19.1M | $21.1M | $40.3M | $47.5M | $30.0M | $19.4M | $38.6M | $41.8M |
| Total liabilities | $3.20M | $2.01M | $3.28M | $3.03M | $3.01M | $19.5M | $21.7M | $20.8M | $17.7M | $20.3M |
| Shareholders' equity | $610.0K | — | $15.8M | $18.1M | $37.3M | $28.0M | $8.30M | −$1.45M | $20.9M | $21.5M |
| Cash flow | ||||||||||
| Operating cash flow | −$202.0K | −$9.11M | −$10.6M | −$15.2M | −$13.5M | −$29.4M | −$37.6M | −$24.5M | −$29.8M | −$49.5M |
| Capital expenditure | $46.0K | — | $46.0K | $53.0K | $17.0K | — | — | $21.0K | — | $3.00K |
| Free cash flow | −$248.0K | — | −$10.7M | −$15.3M | −$13.5M | — | — | −$24.5M | — | −$49.5M |
| Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | Q3 FY26Sep 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Net income | −$12.4M | −$12.8M | −$12.7M | −$14.4M | −$14.7M | −$10.2M | −$74.8M | −$12.1M |
| EPS (diluted) | −$0.36 | −$0.37 | −$0.37 | −$0.28 | −$0.26 | −$0.19 | −$0.80 | −$0.11 |
| Balance sheet | ||||||||
| Cash and equivalents | $12.8M | $13.0M | $51.9M | $31.9M | $20.9M | $28.1M | $48.0M | $59.7M |
| Total assets | $38.6M | $27.4M | $58.9M | $52.0M | $41.8M | $33.1M | $190.4M | $206.4M |
| Total liabilities | $17.7M | $17.1M | $17.3M | $18.4M | $20.3M | $22.4M | $205.1M | $25.7M |
| Shareholders' equity | $20.9M | $10.3M | $41.7M | $33.6M | $21.5M | $10.7M | −$14.7M | $180.7M |
| Cash flow | ||||||||
| Operating cash flow | −$9.19M | −$11.1M | −$9.07M | −$11.3M | −$18.0M | −$6.93M | −$10.8M | −$8.36M |
| Capital expenditure | — | — | — | — | — | — | — | $33.0K |
| Free cash flow | — | — | — | — | — | — | — | −$8.39M |
From Achieve Life Sciences's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →